Pseudomyxoma peritonei medical therapy: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| (16 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Pseudomyxoma peritonei}} | {{Pseudomyxoma peritonei}} | ||
{{CMG}}{{AE}}{{ | {{CMG}}{{AE}}{{Nnasiri}} | ||
==Overview== | ==Overview== | ||
Pseudomyxoma peritonei (PMP) is a rare condition consisting of [[intraperitoneal]] [[mucinous]] [[tumors]] and [[ascites]], most commonly arising from [[mucinous]] [[tumors]] of the [[Vermiform appendix|appendix]] and less commonly from [[ovary]] and [[colon]]. Pseudomyxoma peritonei symptoms include [[abdominal distention]], [[bloating]], [[hernia]], and [[infertility]]. It is a very uncommon [[tumor]] with an [[incidence]] of 0.1 people per 100,000 per year, slightly more common in the [[female]] gender with a median age of 50 years at the time of diagnosis. [[Prognosis]] is good in general. Pseudomyxoma peritonei is [[Histology|histologically]] classified into [[disseminated peritoneal adenomucinosis]] (DPAM), [[peritoneal mucinous carcinomatosis]] (PMCA). Mainstay of treatment is cytoreduction surgery combined with [[hyperthermic intraperitoneal chemoperfusion]] (HIPEC). | |||
==Medical Therapy== | ==Medical Therapy== | ||
Mainstay of treatment for pseudomyxoma peritonei is cytoreductive surgery combined with [[intraperitoneal]] [[chemotherapy]] with [[mitomycin]] at 42°C.<ref name="ChenHuang2008">{{cite journal|last1=Chen|first1=Chin-Fan|last2=Huang|first2=Che-Jen|last3=Kang|first3=Wan-Yi|last4=Hsieh|first4=Jan-Sing|title=Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin / fluorouracil /leucovorin (FOLFOX4)|journal=World Journal of Surgical Oncology|volume=6|issue=1|year=2008|pages=118|issn=1477-7819|doi=10.1186/1477-7819-6-118}}</ref><ref name="Sugarbaker2006">{{cite journal|last1=Sugarbaker|first1=Paul H|title=New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?|journal=The Lancet Oncology|volume=7|issue=1|year=2006|pages=69–76|issn=14702045|doi=10.1016/S1470-2045(05)70539-8}}</ref><ref name="pmid19567401">{{cite journal |vauthors=Vaira M, Cioppa T, DE Marco G, Bing C, D'Amico S, D'Alessandro M, Fiorentini G, DE Simone M |title=Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience |journal=In Vivo |volume=23 |issue=4 |pages=639–44 |date=2009 |pmid=19567401 |doi= |url=}}</ref> | |||
== References == | == References == | ||
| Line 28: | Line 17: | ||
{{WikiDoc Help Menu}} | {{WikiDoc Help Menu}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
[[Category:Up-To-Date]] | |||
[[Category:Oncology]] | |||
[[Category:Medicine]] | |||
[[Category:Gastroenterology]] | |||
[[Category:Surgery]] | |||
Latest revision as of 13:27, 3 April 2019
|
Pseudomyxoma peritonei Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Pseudomyxoma peritonei medical therapy On the Web |
|
American Roentgen Ray Society Images of Pseudomyxoma peritonei medical therapy |
|
Risk calculators and risk factors for Pseudomyxoma peritonei medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]
Overview
Pseudomyxoma peritonei (PMP) is a rare condition consisting of intraperitoneal mucinous tumors and ascites, most commonly arising from mucinous tumors of the appendix and less commonly from ovary and colon. Pseudomyxoma peritonei symptoms include abdominal distention, bloating, hernia, and infertility. It is a very uncommon tumor with an incidence of 0.1 people per 100,000 per year, slightly more common in the female gender with a median age of 50 years at the time of diagnosis. Prognosis is good in general. Pseudomyxoma peritonei is histologically classified into disseminated peritoneal adenomucinosis (DPAM), peritoneal mucinous carcinomatosis (PMCA). Mainstay of treatment is cytoreduction surgery combined with hyperthermic intraperitoneal chemoperfusion (HIPEC).
Medical Therapy
Mainstay of treatment for pseudomyxoma peritonei is cytoreductive surgery combined with intraperitoneal chemotherapy with mitomycin at 42°C.[1][2][3]
References
- ↑ Chen, Chin-Fan; Huang, Che-Jen; Kang, Wan-Yi; Hsieh, Jan-Sing (2008). "Experience with adjuvant chemotherapy for pseudomyxoma peritonei secondary to mucinous adenocarcinoma of the appendix with oxaliplatin / fluorouracil /leucovorin (FOLFOX4)". World Journal of Surgical Oncology. 6 (1): 118. doi:10.1186/1477-7819-6-118. ISSN 1477-7819.
- ↑ Sugarbaker, Paul H (2006). "New standard of care for appendiceal epithelial neoplasms and pseudomyxoma peritonei syndrome?". The Lancet Oncology. 7 (1): 69–76. doi:10.1016/S1470-2045(05)70539-8. ISSN 1470-2045.
- ↑ Vaira M, Cioppa T, DE Marco G, Bing C, D'Amico S, D'Alessandro M, Fiorentini G, DE Simone M (2009). "Management of pseudomyxoma peritonei by cytoreduction+HIPEC (hyperthermic intraperitoneal chemotherapy): results analysis of a twelve-year experience". In Vivo. 23 (4): 639–44. PMID 19567401.